The GLP-1 effect: reformulating for a generation that eats less but better
GLP-1 agonists (Ozempic, Wegovy and successors) are no longer a niche: the user base runs into tens of millions and is growing fast. They change how people eat — less by volume, prioritising nutritional density.
About two-thirds of users eat less overall, and a large majority actively seek high-protein foods. For food & beverage, this is a reconfiguration of demand, not a passing fad.
Nutritional density over volume
Because these consumers eat smaller portions, every bite must deliver more: more protein, more fibre, fewer sugars and empty calories. Major bakery and dairy players are already reformulating their ranges around this logic.
The R&D challenge is not adding a protein, but recomposing an entire recipe — texture, taste, cost, nutritional values — while respecting regulatory and claim constraints.
Portions and formats rethought
The shift also hits formats: smaller portions, split snacks, packs suited to reduced consumption. Every new format is a new SKU to specify, cost and validate.
The real cost: iteration speed
The market rewards those who reformulate fast and well. Yet comparing variants — nutritional impact, material cost, footprint, claim compliance — remains manual work in most companies, stretching time to market exactly when it should accelerate.
What this means for your product data
Answering the GLP-1 effect means iterating over dozens of variants while seeing, in real time, each change's effect on protein, fibre, sugar, cost and available claims.
A PLM that consolidates those values on the fly, handles variants and verifies claims at formulation time turns a months-long reformulation cycle into a few weeks. That is what crumble-ai enables: formulating for the new demand without losing the data thread.
Is your portfolio ready?
See how crumble-ai continuously audits your recipes and blocks non-conformities at the source.
Book a demo